In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex AI is Google's platform for developers to build, train and test generative-AI apps. As of this week, it has some new music features.

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Suzanne is a ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best diabetes stocks to buy according to billionaires. The WHO ...